To determine if the genetic modifiers of tau levels identified in the screen could also modify tau levels in vivo, TCS1, a candidate gene identified from primary and validation screens in neuroblastoma cells, and further validated in neurons, was selected for in vivo validation. Here, MAPT is linked to neuroblastoma.